Genentech’s Dilemma: Avastin Vs. Lucentis Harvard Case Solution & Analysis

IMD-3-2004 © 2008
Boscheck, Ralf

On the October 19th, 2007, Herb Kohl, the chairperson of the SENATE's Unique Committee on Aging, asked Genentech to clarify its choice to restrict the accessibility of its item Avastin in favor of its more costly drug Lucentis, both used in the treatment of damp age-related macular deterioration. In the year 2007 age-related macular degeneration (AMD) was the foremost reason for serious vision loss in individuals over the age of 65 in the Western world.

In the United States, more than 1.6 million individuals had one or both eyes influenced by the innovative phase of AMD, another 7 million were approximated to be "at danger" and more than 230,000 individuals were considered to be legitimately blind due to it. The direct expense of disease related to AMD was approximated to be above $10 billion each year. Wet AMD (wAMD) represented 10 % to 15 % of the cases.

Subjects: Off-label drug use; Food and drug administration (FDA); Age-related macular degeneration (AMD); Biopharmaceutical industry Settings: USA; Biopharmaceutical; 2007 revenues USD 11,724 million; 2007

Other Similar Case Solutions like

Genentech’s Dilemma: Avastin Vs. Lucentis

Share This